Studies and Evidence

Despite a high vaccination coverage in the EU, whooping cough is not only present in Europe, but is dramatically on the rise in the post-pandemic era. Several countries reported outbreaks or increasing numbers in 2023/24...

Learn more

The Vivalytic Urinary tract infection (UTI) test, currently under development, represents a qualitative PCR-based microarray test able to detect twenty-one specific uropathogenic bacteria and seven associated antimicrobial resistance genes in a point-of-care (POC) setting in four steps within 146 minutes...

Learn more

In a comparative testing published by our distributor Aprimeo, the innovative Vivalytic system is compared with standard RT-PCR diagnostics. The study on screening for sexually transmitted infections (STI) was conducted in a fertility practice clinic in Hamburg.

Learn more

M. genitalium (MG), M. hominis (MH), U. parvum (UP) or U. urealyticum (UU) are bacteria without a cell wall. They are either considered as pathogenic or commensal living organisms in the urogenital tract. They belong to the category of sexually transmitted infections in men and women...

Learn more

Since the appearance of the virus SARS-CoV-2 in 2019, in Germany different testing strategies have emerged in order to meet the growing demand of available tests to avoid a further spreading of the disease.,,

Learn more

Point of care diagnostics has increased rapidly in recent years. Physicians and patients increasingly expect to obtain rapid, high-quality test results at bedside and at physician’s practices for immediate diagnosis and based upon the results, optimized patient treatment.

Learn more

The ongoing pandemic of SARS-CoV-2 requires the availability of accurate and rapid diagnostic tests, especially in some clinical settings like emergency and intensive care units (ICU). The objective of this study was to validate the rapid PCR kit Vivalytic SARS-CoV-2 in lower respiratory tract (LRT) specimens.

Learn more